Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly reports a "positive" reception in India for its diabetes and weight-loss drug Mounjaro, having sold over 81,570 units totaling 239.4 million rupees ($2.76 million) as of May, with sales rising 60% between April and May. The company is focused on meeting demand in India, where obesity and diabetes rates are climbing, and anticipates increased competition as Indian drugmakers develop cheaper versions of weight-loss drugs in a market estimated at $150 billion by the early 2030s.

Analysis

Eli Lilly (LLY.N) is experiencing a notably positive market entry in India with its obesity and diabetes drug, Mounjaro, having sold over 81,570 units, generating approximately 239.4 million rupees ($2.76 million) as of May. This initial success is underscored by a significant 60% month-over-month sales increase between April and May, as reported by PharmaTrac. This positions Lilly ahead of competitor Novo Nordisk (NOVOb.CO) in accessing India's substantial market of 1.4 billion people, where obesity rates (24% of women, 23% of men aged 15-49) and diabetes prevalence (projected to reach 124 million adults by 2045 from 74.2 million in 2021) are escalating. PharmaTrac suggests Mounjaro's mass-market pricing could establish it as a key treatment in India. To address the high global demand, which has previously led to shortages, Lilly has invested over $50 billion since 2020 to enhance global production capacity and affirms its commitment to meeting Indian demand. However, the long-term landscape includes emerging competition from Indian drugmakers aiming to produce cheaper alternatives, particularly as semaglutide, the active ingredient in Novo Nordisk's Wegovy, is expected to go off-patent in India in 2026, targeting a global market estimated at $150 billion by the early 2030s.

Key Decisions for Investors

• Investors should view Eli Lilly's strong initial Mounjaro sales and strategic market entry in India as a positive catalyst for near-term revenue growth in emerging markets, given the significant unmet medical need.
• Monitor Eli Lilly's execution on scaling production to meet sustained Indian demand and its pricing strategy effectiveness against future lower-cost generics, especially post-2026 when competitor patents may expire.
• Consider the competitive implications for Novo Nordisk, as Lilly's first-mover advantage with Mounjaro in India could impact market share dynamics in this key growth region for GLP-1 drugs.